This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Pegsunercept
Description: PEG sTNF-RI is a recombinant version of naturally-occuring soluble tumor necrosis factor receptor I, a cytokine playing a fundamental, complex role in various inflammatory processes. Among its many actions is its ability to reduce the inflammatory effects of TNFa.
The recombinant protein is conjugated to polyethylene glycol (PEG) to extend its half-life after injection, a strategy that Amgen has used successfully with Neulasta.
PEG sTNF-RI News
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: